193P - Experience with olaparib in the treatment of BRCA-associated tumors in real clinical practice: Experience of re-challenge mode of olaparib usage

Background

The PARP inhibitor olaparib has shown promising results in the treatment of patients with BRCA-associated tumors. By revealing more and more tumors, the development of which is caused by disorders in the BRCA gene, PARP inhibitors are also expanding their indications. Olaparib shows statistical improvement in ovarian cancer, breast cancer, prostate cancer and pancreatic cancer over standard options while showing a moderate toxic profile. All this makes olaparib a significant option in the planning of patient treatment tactics. In the study, we analyzed cases of treatment with olaparib in an oncology dispensary in the Ufa. Among 79 patients treated with olaparib, median progression-free survival reached 12 months, with disease stabilization being the best response. Among patients treated with olaparib in the re-challenge regimen, the median progression-free survival was 6 months, the best response was disease stabilization. Olaparib has shown satisfactory results in real clinical practice.

Methods

The aim of our study was to evaluate the effectiveness of olaparib in real clinical practice in our region and to demonstrate the clinical experience gained in the regional oncology dispensary. In the study, we analyzed cases of treatment with olaparib in an oncology dispensary in the Ufa.

Results

Among 79 patients treated with olaparib, median progression-free survival reached 12 months, with disease stabilization being the best response. Among patients treated with olaparib in the re-challenge regimen, the median progression-free survival was 6 months, the best response was disease stabilization. Olaparib has shown satisfactory results in real clinical practice.

Conclusions

Olaparib as maintenance treatment significantly improved progression-free survival among patients with platinum-sensitive, relapsed, high-grade serous ovarian cancer. The toxicity profile of olaparib in this population was consistent with that in other populations.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.